TNDM - Earnings call transcript Q2 2018 | Tandem Diabetes Care, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and thank you for your patience.

You've joined Tandem's Second Quarter 2018 Earnings Conference Call. [Operator Instructions] As a reminder, this conference may be recorded. I'd now like to turn the call over to your host, Chief Administrative Officer, Ms. Susan Morrison. begin. may you Ma'am,

Susan Morrison

about Good most or press annual Quarter and Today's XX-K, We XXXX statements. operating Form management's include SEC Hajib. and development report of release the joining today's performance financial discussion you Tandem's these the Tandem's forward-looking and report whether expectation reflect statements Second Earnings and These any on events, of implied today afternoon, you, quarterly product list and thank CEO, timelines speak in leading a everyone, call. results Form result could earlier plans, for will in future Thank date. Conference from those materially actual today's of statements assume and to forward-looking our as be our from factors. differ statements. who'll are and under by President risks any and Kim? now is our obligation materially future recent other that statements our issued uncertainties filings. Kim those publicly be or Blickenstaff, to projected of that results to portion only other risk expressed There could cause on forward-looking as A call. over or cause highlighted to in factors I'll XX-Q information, factors actual forward-looking no in new different and update events call turn elsewhere anticipated

Kim Blickenstaff

to everyone welcome And Susan. call. Thanks, today's

development exceeding progress, we all It's I'm XXXX. a throughout began big the by We delivered in aspirations grow business. me with goals Vosseller, Joining quarters Financial and meeting and fronts X first tremendous the is Leigh operational of or the half on that Chief product our been proud first our year Officer. to

t:slim year-over-year which our compatible Basal-IQ the than monitoring FDA X insulin sales, with integrated first highlights margin growth, delivery of glucose algorithm, a achievement XX year-over-year designation quarter consecutive The iCGM. earlier with record technology, and or points t:slim Mark receipt continuous include: the the the as approval of sales is the of the our from entered initiation third and has of the of launch featuring XX% gross devices, QX our Some pivotal improvement, to significant automated license anticipated CE international positive the of half TypeZero; t:slim The XX build, pump. due for primarily the efforts XX IQ we for the trial technology, with approval momentum and algorithm in high the the of with Control for demand second continued to XXXX year. to we prepare

in we included press in our deliver X our stood and business today's came our quarters in release, first will confidence increase out. As success second looking In that where things our growth. sales the from the continued guidance quarter, reflects X

of our multiple to have people we using of and people that pumps First therapy being success is continued great continue injections is in insulin a using to customer report been to Expanding goal our of company, new great for goal. daily pump strategic therapy. evidence new the pump half about having always this attracting number achievement the has

compared twice notable to pump we saw increase conversions to In a from that, twice this year. the of last and were in t:slim volume, that If to choosing of many we what quarter, from many as a were Animas Second convert Animas QX number as QX. is to who customers Medtronic conversions Medtronic similar saw XX. new we the saw conversions

player emerge as market a a capturing continuing expanding the market the both is pump is that of space. Tandem overall in share the in sign is healthy success insulin significant market and Our and to

customer our pumps. a and a more as we is important to indicator reported improvement also that high I'm something it annual guide helps area of satisfaction the an feedback second our but the key we proud particularly efforts, for meaningful or survey, strategic continuous continued growth extremely our In intentions. to with our is owning quarter, be adoption, Renewals customers Now continuing is of see receive our rate completed we and customer t:slim XX strong the customers' frequency is to of off our technology, of focus many important experienced An which momentum will launch renewal duration to the start. a for We than of to QX is quarter and pumps we of events continue designed or us, help with few and more in is anticipate already twice shipped quarters QX positive hypoglycemia. upcoming reduce second year. driver Basal-IQ to the as compared low-glucose we've as last these renewal

We low-glucose at spend, great users availability offer decision predictive also our the on of our feature diabetes on enthusiasm are not or the States no in-warranty community, our of to XX but about United seeing in feature this pump, t:slim the PLGS only cost.

into As glucose future heading. are levels insulin glucose suspends the with It a begin to delivery where resumes predict our technology levels reminder, t:slim is predicted look insulin when Basal-IQ low to once minutes delivery to is designed rise. XX automatically glucose then and XX

relative sharing feature. as Our time to a data larger pursue clinical part is Basal-IQ payers enabled without pump it compared mg/dL reduction are believe our using hypoglycemia, pivotal a with insulin and strategy no with trial below We CGM more XX direct and actively to compelling of this we demonstrated contracts. in spent rebound a XX% this

requires our of a this or with devices. or users now least per in is most at t:slim also GX significant decisions. insulin sensor for pump designated we're Dexcom's is compatible year. compatibility have our the iCGM to accurate the with as treatment the launch eliminate fingersticks also that original fingersticks This this available, to over CGM, time Our line XX and course put XX yet diabetes X,XXX perspective, means more fingersticks ahead of can single XX than Dexcom's the To week of first able calibration as pump pump which no GX

not quality customers. to We for into translate to improvement, Tandem this cost expect of reduction life measurable mention

is begin With to screen so this to additional use we’ll feature to that IQ XX August, to and is minutes training in for the Basel XX We new software typically in training pumps to users be on one are shipping track out only rolling concurrently through to able the existing t:slim on module. pump to XX a be learn, done easy web-based customers.

software Following Control-IQ, are working automated launch the insulin XX of second Basal-IQ, delivery on update with next generation the we for system. t:slim our

GX It for we to and basal for sensor leapfrog competing been Control-IQ the minimize boluses, correction reminder, to providing a utilize the was iCGM designed range. products insulin that customers. is intend also and or targeted designed improve As by which and licensed bring we values Dexcom’s hypoglycemia from decrease or user's will spent we increase hyper to technology AID to system time benefits within our the additional TypeZero. glycemic automated believe

or into We our PMA of FDA began using study to Pancreas module, are the which and our data working with Clinical the well. the integration in modular this from to the and submission Artificial technologies is the portion first FDA, September. submit progressing the be Dexcom Acceptance Enrollment plan IDCL and of TypeZero via trial. of We’ll DCLPX of we on June in

at is for waiting more until submission to compared is won’t resolve conclude a hopefully expedited of the PMA available next sections. in more review year, it all data This modular until study to traditional the the allows will that review benefit submission. the While agency process

with launch is t:slim Control-IQ subject goal to summer the FDA to Our in approval. XXXX, XX of

other last systems Our Basal is Launching year their anticipated intended Control-IQ product IQ Updater, outcomes. provide not releases. offer automated improve we but management of the continuing with clinical are to to to allows to Device for capability experience pump next insulin by company. year, are in-warranty It remarkable offered XX insulin ultimately exciting customers, their the through integration customers, Tandem also GX able delivery efforts to our us customers innovation only year existing that therapy use our features this cadence and a our t:slim deliver new a can and launch to no

growth longer-term the company. driver a for to Turning

notable outside Australia, the CE our entered in was end United Africa, South at Today, t:slim progress with in We and are New to the markets independent excellent Most Italy, of receipt preparation our distributors into the Kingdom. of Zealand, agreements United launch Spain efforts. Mark contracting active making Scandinavia, upcoming we States and on XX for our months. April of the have

to X our While half we the think distributors about multiple there isn’t by with meaningful great driver We’ll on representation, country, what international year this years. countries our market of type in launch. and know the chosen strategically is number be few a customers will diabetes represents of modest we international globally. that it’s converting injections data next daily an color be we we closer underpenetrated of and on and additional growth future people the believe fact opportunity history the exact our of meaningful With providing over expansion upcoming to our Animas

delivery discuss algorithms, DCT will year, amidst Conference and that track so XXth taking in automated efforts, the place updated host happening OUS and an in to the we’ll is company. progress. our with these great as San XXth the you on plans the Los San to longer-term With Diego insulin along NASS conference Diego strategy the things for which the Cardiology on at we’re Investor at many our we business Angeles. about here day-off of more place international taking between happenings September We’re in continue we our with September company, the this planning spine Institutional and shipments Analyst keep make and day

to to us. who join So trip we welcome any med tech the anyone event will make webcast. conferences would Diego or also these to San to The be like folks

I’ll the to quarter Additional through are for discuss details our the year. turn updated results call for available guidance of the our Investor further website. to on Leigh over registration and Center the information now

Leigh Vosseller

and Kim, everyone. afternoon, you, Thank good

XX% to sales over million press year. approximately the this X pumps have XX,XXX reasonable a Upgrade be continue estimate XX,XXX We in to at with our at quarter, in driver quarter and the quarter year. growth basis. our than double most year-over-year, renewals Pumps This even million you benefit $XX It of sales quarter. that shipped approximately sales is demonstrated strong second-highest time. results on representing this an year-to-date release, which second now drove growth shipped a again the shipped quarter of of XX% we to installed We the execution Technology the strong compared nearly recognized related pumps renewals saw prior in history, consider in XXX XXXX QX, which $XX shipped or basis on million, increase years, a last in current and million. we XXX or the in that more in brings significant As this us an XX% today's and Since over the $XX to equally in of $X.X last base. was the with Program our XX% QX year-to-date both to total solid we X,XXX inception, place

feature, to increase from quarter. to can deductible Infusion we renewals in million expect increased million. to insurance fourth rate. $X the the combined heavily years half raising high pump $XX $XXX sets with in to a we we weighted X to our experienced XX% in time total on our more that range quarter This million for Consistent of X-year of began sales capture sales take Supplies XXXX XX% to to sales are As resets. the a quarter overall of customers, see the late timing shipping renewal in supplies due also at $XXX ordering the a sales million by second for with a year-over-year significantly guidance seeing reminder, the to we and particularly a sales the Based far XXXX the of entire ultimate XX% to range period. row. historical $XXX renewal and of pumps install be our $XXX from million infusion year set million. to our base in on pattern, was Based a reach to of were cycle, the so result suggests of the XX% this strength second continue we typical sequentially of have previous to the X that it QX. goal level increased Basal-IQ interest sales and from of are new pumps, Similar our our

set XX%, new our to the continue beginning our first of and the manufacturing prior have sales. profits Growth XX% year. year Higher volume to XXXX. as drive efficiencies modest greater well and in infusion in quarter for quarter up international sales guidance Kim second this As margin to process XX% in later increased from from expectations only improvement mentioned, continue range as the incremental cost in

freight, reflected primarily other versus product warranty, will new whole, Other and distributor a which trainings to margin continue that As nonmanufacturing gross mix. customer have direct mix are of impact seasonality, factors improvement. also and and cost, consist

noncash this XX% second compensation dropped for is original associated half X-point expenses with impacted flow were At are range reaching progression second million grant $XX not margin compensation. benefited just for XX% at XX% Our year. $X related in breakeven our prior in This $XX With is additional was to $XX of warrants our an months. sales quarter in from the investments, ended margin is which end, the million stock to $XX XX%. in to line million significant gross this guidance point, QX. cash we is million of negative our of in approximately our of until the the $XX margin and margin to goal option nearly in which point we adjusting in the the by our million charged our a now proceeds our from of to million million cost in Overall, higher compensation $XX to over quarter, primarily expected incentive-based of anticipated non-cash growth, up gross due stock-based and pipeline Operating improvement XX $XX of year-over-year, XXXX. single-digit in the up increase recent from sales cumulative our We Total were year-over-year goods quarter, which cash amounts increases noncash appreciation that, end In the stock-based QX negative in These of negative the XX% by with costs warrant prior in reduced range quarter bringing evaluation results. expense product to approximately result includes XXXX XX% in year, which reflects R&D primarily with recent over to the improvement increase a our the operating above-expectation overall our operating increase the of year. increase X% a the beyond did negative exercises, the million total million as from to in half expire sold year, $X of expense price in employee XX% which compared increases negative a toa be the and is from drove a to XXXX. compensation, considering well total expectations our stock-based even previous QX. of operating offset guidance

carefully with priority $XXX to we expect as annual to our it view addressing for a our cash these summary, use to QX. our use in down XX% This are to stock-based recent million is operating prepare evaluating approximately of lower and guidance QX and replenish negative sales than options to Excluding and increasing compensation $XXX of an continue we years, expenses prior for do we notably our with nearly to was sequentially and better highly XX% to though, increase $X for a we includes it. balance, Consistent range for year all QX.With level only inventory depreciation regard outstanding XX%. debt and margin In million both $XX a range have in seasonal which quarter, XX% million than amortization. the proceeds, in noncash million cash been as the our negative

us to base. ordering turn at the have on questions. we breakeven operator With cash in than our that to I the that, will in expect is confident flow which time sufficient for to are second more it customers installed We XXXX, half XX,XXX cash of over our hand sustain to

Operator

comes [Operator line Thank Instructions] question McKim first J.P. Piper of from Jaffray. Our the of you.

open. Your line is

J.P. McKim

in you've afternoon, the launching of wanted Good on I August. here touch and Basel-IQ got momentum-wise, to international a congrats you've going here. first on got strong mean, And just I quarter guidance. great lot and on things got you've

So for there's an one potential can acceleration. argue

sense half terms back more need conservative now the of expectations. thinking trying of look something I'm how out a more kind And in as of to at about get is guidance this watching should be you're or So in we deceleration for to we people's specifically?

Leigh Vosseller

the question. thanks JP, for

to all, what I reiterate philosophy overall want guidance is. of just our First for

we set the to the on that we for year the enthusiasm so with based of on we saw factors expectations that achieve. It's that saw far. half feel that can continue And change, that to very really, We a of Basal-IQ first lot the has confident early. the strength the in and still it we

with getting see just go to sure will we not that hard want the things make of part, it's to So most that. ourselves. for But where ahead we’re

the what and renewals this than those really, we other set infusion sales. for year expect also the to so guidance, in down factors, And comes growth for

J.P. McKim

it. Got

for still is in international sound earliest. QX year. like, minimal that theory, get does in So But some the it here Is could you fair? at the shipments

Leigh Vosseller

Yes.

So going when Day have you how and forward September. at Analyst lot the giving the more look our we are the about get opportunity to we Investor starting. And timing color end and as long whole international a a at a time, on to information more lot we’re of to things of the that

J.P. McKim

increased just it. our lot since demand got on calls last you for have Basal-IQ suggested, you've to, A Got alluded like the me for Basal-IQ. that GX. of And the Tandem one has

jump could you maybe today So the ago to is up there changed framing in frame maybe any demand compared how the And approval? kind up that pipeline of months have this by six way that you pipeline? has now

Leigh Vosseller

Basal-IQ question validity world anticipating a were it It’s ago our we plans the simple right the And months now took was with that came developed year. the we around for we whole same that off different originally time when the X financial than basically anyway Yes. table. the fact

and track more the guidance to raising just on million to that $XXX range us gives it right really confidence even million. $XXX So in

Operator

you. Thank

Our of Doug next the question Cowen. of comes line from Schenkel

now line Your open. is

Doug Schenkel

for and questions. thank our you afternoon, taking Good

Just XX. - starting move launches foreseeable X meaningful off Have you on sorry, long-term X,XXX come have - shouldn’t of increase t:slim X,XXX know X the Basal-IQ your seeing future, that I'm rates the new the XX% purchased renewals. of warranty interest I Control-IQ being and to We to the total over long to believe patients catalysts over over any after quarters? renewal goal Basal-IQ expect approval? the but the about you next have towards even over XX increased the recently a

Leigh Vosseller

Yes.

And and So for say think need lot but But it's that is road. to to the thanks to us early there's it. still could people the - understand communication on had product impact for would to see can accelerating mostly go available an of what of out the they we we if that the down cycle, What because renewal Doug. and we we algorithms advanced of the that approval calling in, again, to factor adjustments I go us it expect about accelerating looking to get do help be be that announced forward factor because can be those so they forward. what is a do an

Doug Schenkel

not but a or question. I answer take to I Okay. am growth if shot going you’re not, going sure to And anyway. try am I’ll longer-term at it

Consensus reasonable this are to talked better appearances are that, XX% a next public to about way believe Can to numerous previous catalysts What's XX% expectation year. moving on forward? even and you XX% you well position talk for think year. you've if you revenue the call to future. would about over reasonable this grow track seem expectations about in term? is anything, on what a You longer But this revenue growth even

Leigh Vosseller

year. a year, narrow and market, good for I had key we in us. up opportunity coming have the really in really one one of this think We are this about it presented amazing of window where has particular, year this time a competitors very thing and we -- next few products the

when of of any long-term, the the specifically is what for see competition to to have possible and into opportunity. year we're as So come other customers players we'll the next in to where plan do take many this of with lot the advantage But What give few market. to going I'm and numbers see we market. you time this opportunity a players but one definitely not this capture happens the window have we while we as of

Operator

you. Thank

Hopkins Robert of next Our America. of question comes Bank from

is line Your open.

Travis Steed

Thanks This Steed Bob. on taking question. for the is Travis for

Just term very wanted thinking your you've you on then are and and can with but take the a GX balanced competition. what IQ? With got with Control competitive to that's market obviously your share your Basal-IQ rate again, of with product, win size longer comment pump a go

in So those to just just curious thoughts puts from hear your a where takes play high out on of level and mind? kind your

Leigh Vosseller

hard are we the this on go. such can established is say where implies, right it market, whatever unusual us. XX% share. time It's to an truly, about I where now, your With for exactly are it But assumptions based have market mean, we that

us with still big And opportunity is I to year we great But seen. really have opportunity we for a think, the out in patients there where take next report those be again, Animas is and or as X. a decisions available to position make so lies to here that their

Travis Steed

mentioned the more and payers that any coming? making performance color some just Thank and have you progress with that guarantee impact you then you there in curious marketplace? follow-up now will just also, And of Basal-IQ about contacting And that. the kind to in of the of the that you. new you're talk as a conversations your you if Medtronic's I Okay. have

Kim Blickenstaff

program candidates Thanks. it's who's is to have actually to hospitalization Well, reimbursed. cost be that clear going how that to not going work and completely

goal think is hypoglycemia outcomes reduce implication. saw to negative outcomes. try as trials. much we clinical we hospitalization of it's based I that our to the as this can our to negative sort on eliminate from They to have guarantee a And

rather and reimburse is strategy our costs that's save then to our system system have So have costs them the from them. really than to incur

forward with important one. we'll we position actively We're players. benefits a think you the the I our an progress really the really Control-IQ, In to major we're begin that. outcome to and system make now question update doing is and Basal-IQ terms payer, going And of in showing of the as

Operator

Thank you.

Our the of Wise comes Stifel. next question Rick of from line

Your question please.

Matt Blackman

Good couple past I'm I think start A actually patients Rick. with international the Matt are Animas going said of least you've It's everyone. Blackman the half at of to in And those afternoon, questions. the for U.S. opportunity. Animas outside

can that after already regions? little going last be So quickly bit of get -- guess is at to a detail does concentrated then bit that start can all of disclosed top up. quick I a are talk you part You've about those intentions because And opportunity? to in have of a a in little follow your head geographies? you on how it, I bit opportunity more a how build talent you have capabilities. And the And disadvantaged in that, Medtronic

Leigh Vosseller

Sure.

provided their hard was of in where because base first their that folks that's a exit, is so been It's forward. view more distribution the say go many to network give start forward now by correct, you just the And opportunity the that, about the I'll Day and saying international holistic understand OUS. about said when Investor had they we actively are for with people them. what Animas announced engaged were But again, but October XX% where those of this we we for have to having of on today you look stand opportunity, they installed their to

installed lot help up the markets much hope it we world. an us. that's look be into entering nice more give international business established, so we should for But into that understand how color again, step with forward a to pretty so on build And will Investor base to into Day to a those

Matt Blackman

quarter. gross strong the given then the another just if have of? growth performance, expanded, sequential as on the quarter drags growth. be strong we And any thought but not the revenue there aware that the that. I perhaps year-over-year in one obviously, should onetime gross margins on much is appreciate And were with first just margin Anything ask might Gross strong versus curious in volume quarter? I Okay. margin, second as

Leigh Vosseller

moving had anticipated margins. No, along gross actually. is we Everything as just for

expect the to on margins with everything you back past, with do year. is across what year in as our half thought XX% the the get expectations have to As track probably point for we seasonal sequentially But fourth we gross of we seen to the get higher increase right next that that at fully we quarter. would to

Operator

you. Thank

next question Brooks of Street O’Neil Lake from comes Capital. Our

line open. is Your

Brooks O’Neil

afternoon. you Good okay? Can you. me Thank hear

Leigh Vosseller

Yes, we can. Thank Brooks. you,

Brooks O’Neil

Hi, Leigh. is the to I was compensation, year? or stock bit in any is the higher you're units additional just that effect modeling. curious been number strong if have were stock-based price curious we this obviously, am than I issuing on related the entire appreciation your

Leigh Vosseller

latter, the It's Brooks.

in as fourth grants had that we of that well as shareholder grants December the in the So were we issued meeting actually in June. quarter, XXXX, issued conjunction with approval the at

which, been that stock-based price this is tremendous, of has it really around. the has growth that we charge can’t the but comp and basically unfortunate And stock consequence trading so get

Brooks O’Neil

I that completely. understand Absolutely.

ask Let a question. me you different

notable bit you what think, new So what phenomenon? number going think be - and for first a) elaborate Could road? mentioning a just Medtronics I correct this a switchers, you on little seeing a am I the was I Kim think you time might seen b) might that see you're down of the

Kim Blickenstaff

Yes, a Roche, And be Medtronic. the where Delta to I area you past, us back. some going is for think pump space in in forward new and we’re Animas going entering years going durable had

advances now different year have Dexcom last alluded that XXXG And in is a with race. the and we available the it's our So integration think automation. Leigh in then when now wasn’t year really thing didn’t towards the other I the to than widely heading X-player market and

choices of the reduced. are think I been number -- So now have

be a to on a to now can patient a to preferred it’s obviously, going MDI, that’s and forward. different but mean, not pump So holiday the dynamic. going go back care choose I go

also high transfer the insulin been percentage very over So are has not you and to when this choice. making

to as X coming at Animas been have features think Medtronic very who -- as good who have features availability look And very, been of there patients at those we choices. now weren’t and we we patients who advances we look down and waiting, year. waiting, So head-to-head product last renewals, at I have And it's rapidly.

think different it’s a I world. So

Brooks O’Neil

a it’s think different too. I world

I very that leapfrog it's competition, step allow Medtronic? think exciting. forward your to Is another to that will specifically Control sense you the relative IQ

Kim Blickenstaff

for believe believe and going I very eliminating think avoiding to Medtronic said that my out. that's think, anybody get of in I to it ensures fingersticks time advantage and important we correction using will. don't of I be that And I achieving system the will in an enormous high Control-IQ is range I comments, our timeframe low be excursions. XXXG. bolus and the GX Yes, the simplicity resolved our versus also

So going for forward. tailwind to that's going I think a further us be

Brooks O’Neil

about I'm Kim, to it. And excited

Let patients payers have exclude any have particularly your so of comment the your superior. and new. ask I somebody about obviously, program last that the Medtronic that appeal many to from you one Do programs, to to be curious, question. the the features about are that? me fact we kind to trying me by is are you, It seem since that consideration. think strikes guess, But was products earlier, relatively asked just I'm payers going after I patient you struck incentivize I

Kim Blickenstaff

and Well, appeals burden improving the patient honestly reducing terms of believe that I it in control. to

because We're blood the going currently reduce I We're glucose use. getting reduction to outcomes, better people that training somebody also to going and disposables pump, on payers the to consumption hypo be costs, a of at going we're of in getting be hyperglycemia. think it's to the startup that. reducing time to to look appeal going you if

eliminating can system causes. adverse than I extent for outcomes think you that's rather reimbursing counts what that through

I it any term, standing of there. think I just -- give somebody that's is So won't sort other

Brooks O’Neil

No. No.

think pretty Thank very I much. Absolutely. it's you clear.

Operator

you. Thank

Our Lichtman next & Steven comes the of line question Oppenheimer from of Company.

is line open. Your

Steven Lichtman

Thank guys. you. Hi,

Just follow-ups. a few

First, announced from the patients you as conversions and percentages many new noted before? those twice details year-over-year. Animas that on about Medtronic give percent Any teens you through talked exit. can know conversions numbers, I what are? Medtronic provide you they Can that? past those the you Animas of low you go from Can in before

Leigh Vosseller

Yes.

increase Animas the in little overall But way. than with Medtronic converters the makes dynamics is seeing percent converters, coming as Animas continued that increase you we're business. the But a from that's bit that hard XX% what interesting MDI. to talked I'll day about say in to measure more have on the bid very to in the what We it change past a converters, of in still the even

So we're share. rise the out way across it, board. the in typically looking follows it played and and the has healthy Medtronic nice seeing out With a market the Animas way still past

when higher to market in of that they So the with having converters Medtronic comes the that biggest of are market share the it the piece it. percent

Steven Lichtman

now more was Thanks. then, them now wondering pipeline United with with And your Basal-IQ having some to about and your what I Okay. with of M&A, thoughts conversations sort coming? back returning are advanced

Kim Blickenstaff

to be the them think in to effort to I help in to regard can strategy it's control what going and approach an adverse for Well, failures outcome. costs us all do we

ago us when have So to UHC have X we'll they have years We it. be now we didn't on what asked list. that

think a year. a I that's second ahead so we're effort good -- of position half good this that on the in move to in And

Steven Lichtman

pretty this flat further And at sales the talked at the relatively Okay. know stay the keeping point? despite -- you flat big about in this updated Any growth. steady increasing point. sales Any thoughts SG&A force? about Great. the I force thoughts on then sales past it

Kim Blickenstaff

I sales jobs. and Leigh want Well,

Leigh Vosseller

in evaluate we evaluating do year XXXX committed to and growth. as still to opportunity this do force the might sales drive the keeping we it want is the keep what And we and it take at the what continued to or we’ll continue market size to to need

Operator

And you. to I'd turn any call the over time remarks. closing to back Sir? for like Kim this Blickenstaff Thank

Kim Blickenstaff

everyone just joining today. us thank to for Well, I want

a largest myself think had audience call, this again. history good to conference is in our to on we've talking I the talk to crowd rather than it's be so

For the up, hope be Analyst in able are to that’s coming us Diego. XXth to Institutional day join you September we Investor and going here on San

Baird our on also website. conference is be Street reminder, conferences with XXth. on Xth, through We’ll Investor Global and We’ll As September information a the the few the followed attending the September registration York, a available Stanley September. Center on be and conferences in Morgan XXth New in Lake Healthcare the

the Thank keeping forward updated year. for us during much, we're you so again progress continues looking you. everyone, and joining to Tandem today, thanks as So to

Operator

Ladies and a your day. today’s Thank gentlemen, and have conference. concludes participation this wonderful you for

Tandem Diabetes Care (TNDM) 30 Jul 182018 Q2 Earnings call transcript